Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60
Tandem Diabetes Care, Inc. +1.07% Pre
Tandem Diabetes Care, Inc. TNDM | 37.00 37.00 | +1.07% 0.00% Pre |
Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:
TNDM) with a Overweight and raises the price target from $58 to $60.